Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF RIFAMPIN ON THE PLASMA-CONCENTRATION AND THE CLINICAL EFFECT OF HALOPERIDOL CONCOMITANTLY ADMINISTERED TO SCHIZOPHRENIC-PATIENTS
Autore:
KIM YH; CHA IJ; SHIM JC; SHIN JG; YOON YR; KIM YK; KIM JI; PARK GH; JANG IJ; WOO JI; SHIN SG;
Indirizzi:
INJE UNIV,COLL MED,DEPT PHARMACOL,JIN KU,633-165 KAEKUM DONG PUSAN 614735 SOUTH KOREA INJE UNIV,COLL MED,DEPT PHARMACOL,JIN KU PUSAN 614735 SOUTH KOREA INJE UNIV,COLL MED,DEPT PSYCHIAT,JIN KU PUSAN 614735 SOUTH KOREA DONGSUH HOSP,DEPT PSYCHIAT MASAN SOUTH KOREA SEOUL NATL UNIV,COLL MED,DEPT PSYCHIAT SEOUL SOUTH KOREA SEOUL NATL UNIV,COLL MED,DEPT PHARMACOL SEOUL SOUTH KOREA
Titolo Testata:
Journal of clinical psychopharmacology
fascicolo: 3, volume: 16, anno: 1996,
pagine: 247 - 252
SICI:
0271-0749(1996)16:3<247:EOROTP>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
REDUCED HALOPERIDOL; DRUG-INTERACTIONS; PHARMACOKINETICS; MONOOXYGENASE; METABOLISM; UPDATE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
Y.H. Kim et al., "EFFECT OF RIFAMPIN ON THE PLASMA-CONCENTRATION AND THE CLINICAL EFFECT OF HALOPERIDOL CONCOMITANTLY ADMINISTERED TO SCHIZOPHRENIC-PATIENTS", Journal of clinical psychopharmacology, 16(3), 1996, pp. 247-252

Abstract

We assessed the changes of plasma haloperidol concentrations and clinical responses repeatedly np to 4 weeks after coadministration or discontinuation of rifampin in 12 schizophrenic patients taking haloperidol alone (group I) and 5 patients taking haloperidol and antituberculotic drugs (group II). After coadministration of rifampin in group I, daily trough haloperidol concentrations rapidly decreased and reached 63% of baseline level by day 3, 41.3% by day 7, and 30% by day 28. On the other hand, after discontinuation of rifampin in group II, plasma haloperidol concentration increased to 140.7% of baseline level by day 3, 228.7% by day 7, and 329% by day 28. In this study, a 30% or greaterchange in the clinical rating scale was considered a positive clinical response of the drug interaction. Using this criterion, 50% of the group I subjects responded according to the Brief Psychiatric Rating Scale (BPRS) total score, and 25% responded according to the BPRS subscale for psychiatric symptoms. No positive responses were observed in group II patients. These results strongly suggest that rifampin interacts with the clinical effects as well as the plasma concentrations of coadministered haloperidol, and careful monitoring should be considered when coadministration or discontinuation of rifampin is needed in a schizophrenic patient taking haloperidol.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 00:46:53